326 related articles for article (PubMed ID: 24913358)
1. Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme.
Krummenacher I; Spencer B; Du Pasquier S; Bugnon O; Cavassini M; Schneider MP
Int J Clin Pharm; 2014 Aug; 36(4):716-24. PubMed ID: 24913358
[TBL] [Abstract][Full Text] [Related]
2. Implementation study of an interprofessional medication adherence program for HIV patients in Switzerland: quantitative and qualitative implementation results.
Lelubre M; Clerc O; Grosjean M; Amighi K; De Vriese C; Bugnon O; Schneider MP
BMC Health Serv Res; 2018 Nov; 18(1):874. PubMed ID: 30458844
[TBL] [Abstract][Full Text] [Related]
3. An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring.
Krummenacher I; Cavassini M; Bugnon O; Schneider MP
AIDS Care; 2011 May; 23(5):550-61. PubMed ID: 21271406
[TBL] [Abstract][Full Text] [Related]
4. A qualitative study examining HIV antiretroviral adherence counseling and support in community pharmacies.
Cocohoba J; Comfort M; Kianfar H; Johnson MO
J Manag Care Pharm; 2013; 19(6):454-60. PubMed ID: 23806059
[TBL] [Abstract][Full Text] [Related]
5. Barriers and facilitators to antiretroviral medication adherence among HIV-infected paediatric patients in Ethiopia: A qualitative study.
Biadgilign S; Deribew A; Amberbir A; Deribe K
SAHARA J; 2009 Dec; 6(4):148-54. PubMed ID: 20485854
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral adherence program in HIV patients: a feasibility study in the Swiss HIV Cohort Study.
Krummenacher I; Cavassini M; Bugnon O; Spirig R; Schneider MP;
Pharm World Sci; 2010 Dec; 32(6):776-86. PubMed ID: 20862544
[TBL] [Abstract][Full Text] [Related]
7. Pharmacists' strategies for promoting medication adherence among patients with HIV.
Kibicho J; Owczarzak J
J Am Pharm Assoc (2003); 2011; 51(6):746-55. PubMed ID: 22068197
[TBL] [Abstract][Full Text] [Related]
8. Barriers and facilitators of adherence to antiretroviral drug therapy and retention in care among adult HIV-positive patients: a qualitative study from Ethiopia.
Bezabhe WM; Chalmers L; Bereznicki LR; Peterson GM; Bimirew MA; Kassie DM
PLoS One; 2014; 9(5):e97353. PubMed ID: 24828585
[TBL] [Abstract][Full Text] [Related]
9. Individual, social, and structural factors affecting antiretroviral therapy adherence among HIV-positive people who inject drugs in Kazakhstan.
Davis A; McCrimmon T; Dasgupta A; Gilbert L; Terlikbayeva A; Hunt T; Primbetova S; Wu E; Darisheva M; El-Bassel N
Int J Drug Policy; 2018 Dec; 62():43-50. PubMed ID: 30359872
[TBL] [Abstract][Full Text] [Related]
10. Exploring the implementation of a medication adherence programme by community pharmacists: a qualitative study.
Marquis J; Schneider MP; Spencer B; Bugnon O; Du Pasquier S
Int J Clin Pharm; 2014 Oct; 36(5):1014-22. PubMed ID: 25139136
[TBL] [Abstract][Full Text] [Related]
11. Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen's Behavioral Model.
Holtzman CW; Shea JA; Glanz K; Jacobs LM; Gross R; Hines J; Mounzer K; Samuel R; Metlay JP; Yehia BR
AIDS Care; 2015; 27(7):817-28. PubMed ID: 25671515
[TBL] [Abstract][Full Text] [Related]
12. Barriers to and facilitators of antiretroviral therapy adherence in Nepal: a qualitative study.
Wasti SP; Simkhada P; Randall J; Freeman JV; van Teijlingen E
J Health Popul Nutr; 2012 Dec; 30(4):410-9. PubMed ID: 23304907
[TBL] [Abstract][Full Text] [Related]
13. Patient-perceived barriers and facilitators to the implementation of a medication review in primary care: a qualitative thematic analysis.
Uhl MC; Muth C; Gerlach FM; Schoch GG; Müller BS
BMC Fam Pract; 2018 Jan; 19(1):3. PubMed ID: 29304725
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of HIV patients referred to a medication adherence program in Switzerland.
Krummenacher I; Cavassini M; Bugnon O; Schneider MP
Int J Clin Pharm; 2012 Jun; 34(3):426-31. PubMed ID: 22527483
[TBL] [Abstract][Full Text] [Related]
15. Development of an algorithm for analysing the electronic measurement of medication adherence in routine HIV care.
Rotzinger A; Cavassini M; Bugnon O; Schneider MP
Int J Clin Pharm; 2016 Oct; 38(5):1210-8. PubMed ID: 27473709
[TBL] [Abstract][Full Text] [Related]
16. A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse.
Kuchinad KE; Hutton HE; Monroe AK; Anderson G; Moore RD; Chander G
BMC Res Notes; 2016 Apr; 9():229. PubMed ID: 27103162
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacists' perspective of medication adherence support in Ethiopian hospital settings: a qualitative study.
Tegegn HG; Wark S; Tursan d'Espaignet E; Spark MJ
Int J Pharm Pract; 2023 Dec; 31(6):617-624. PubMed ID: 37721550
[TBL] [Abstract][Full Text] [Related]
18. Barriers and facilitators to antiretroviral adherence and retention in HIV care among people living with HIV in the Comarca Ngäbe-Buglé, Panama.
Gabster A; Socha E; Pascale JM; Cabezas Talavero G; Castrellón A; Quiel Y; Gantes C; Mayaud P
PLoS One; 2022; 17(6):e0270044. PubMed ID: 35709223
[TBL] [Abstract][Full Text] [Related]
19. "For us here, we remind ourselves": strategies and barriers to ART access and adherence among older Ugandans.
Schatz E; Seeley J; Negin J; Weiss HA; Tumwekwase G; Kabunga E; Nalubega P; Mugisha J
BMC Public Health; 2019 Jan; 19(1):131. PubMed ID: 30704445
[TBL] [Abstract][Full Text] [Related]
20. Adherence to highly active antiretroviral therapy in Hyderabad, India: barriers, facilitators and identification of target groups.
Dworkin MS; Douglas GW; Sabitha Rani GP; Chakraborty A
Int J STD AIDS; 2016 Mar; 27(3):186-95. PubMed ID: 25801316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
